TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $29.83.

Several equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. restated an “overweight” rating and issued a $25.00 target price on shares of TG Therapeutics in a report on Thursday, April 18th. HC Wainwright raised their target price on shares of TG Therapeutics from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Finally, LADENBURG THALM/SH SH raised their target price on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd.

TG Therapeutics Price Performance

TGTX stock opened at $18.31 on Friday. TG Therapeutics has a 52 week low of $6.46 and a 52 week high of $26.95. The company has a quick ratio of 2.84, a current ratio of 3.62 and a debt-to-equity ratio of 0.63. The company has a fifty day simple moving average of $16.62 and a two-hundred day simple moving average of $16.08. The firm has a market capitalization of $2.83 billion, a P/E ratio of 79.61 and a beta of 2.23.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). TG Therapeutics had a net margin of 14.24% and a return on equity of 31.34%. The business had revenue of $63.47 million for the quarter, compared to the consensus estimate of $54.60 million. During the same quarter last year, the business earned ($0.28) EPS. TG Therapeutics’s revenue for the quarter was up 713.5% compared to the same quarter last year. Analysts anticipate that TG Therapeutics will post -0.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Eventide Asset Management LLC purchased a new position in TG Therapeutics in the 4th quarter worth about $7,506,000. Wellington Management Group LLP increased its position in TG Therapeutics by 1.4% during the 4th quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company’s stock valued at $53,627,000 after purchasing an additional 43,290 shares during the period. Charles Schwab Investment Management Inc. increased its position in TG Therapeutics by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,896 shares of the biopharmaceutical company’s stock valued at $19,333,000 after purchasing an additional 19,214 shares during the period. Corient Private Wealth LLC increased its position in TG Therapeutics by 231.6% during the 4th quarter. Corient Private Wealth LLC now owns 93,381 shares of the biopharmaceutical company’s stock valued at $1,595,000 after purchasing an additional 65,220 shares during the period. Finally, SG Americas Securities LLC purchased a new position in TG Therapeutics during the 4th quarter valued at about $345,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.